Connect with us

Financial News

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

Shares of Novo Nordisk on Monday fell 10% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal.Read More

More in Financial News